8th International Electronic Conference on Medicinal Chemistry
1–30 Nov 2022
Medicinal Chemistry, Pharmaceuticals, Drug
- Go to the Sessions
- Event Details
On behalf of the conference team of the 8th International Electronic Conference on Medicinal Chemistry, we would like to thank you for your participation by sending your contributions, being posters, slideshows or flash communications. We hope you've enjoyed it!
List of accepted submissions (253)
|Id||Title||Authors||Presentation Video||Poster PDF|
Effects of Protein Hydrophobicity on Protein Corona Formation Modes on Soluplus® Nanomicelles
, , , , ,
Submitted: 02 Jul 2022
Abstract: Show Abstract
|, , , , ,||N/A||
Soluplus® nanomicelles have been rising as excellent drug carriers for their great drug loading capacity. Nevertheless, the protein corona would formed when subjected to biological fluids, but few efforts have been made in elucidating that. Here, the effects of protein hydrophilicity on protein corona formation modes were investigated based on three model proteins, Bovine serum albumin (BSA, hydrophilic), Lysozyme (Lyso, hydrophilic) and Bovine hemoglobin (BHb, more hydrophobic). Protein corona formation was proved by the size and zeta potential measurements, while the size increments of BHb group were the most significant. We hypothesized that the hydrophilic protein might be dominated by the surface adsorption mode, where the proteins were cross-linked by the out-layer PEG chains. However, the hydrophobic protein may show insertion mode, where the nonpolar part was inserted into the hydrophobic core of nanomicelles and the polar part distributed on the surface. To justify this hypothesis, the microenvironment polarity of hydrophobic tryptophan (Trp) acid amino residue was analyzed. The most obvious peak wavelength changes and the minute absorbance change were exhibited in ultraviolet-visible spectra of the BHb group, indicating the hydrophobic Trp was distributed in the nonpolarity core of nanomicelles. This conclusion was further proved by the similar results in fluorescence emission wavelength. In addition, the circular dichroism results confirmed the obvious arresting conformational change induced by insertion mode protein corona formation. In summary, the hydrophilic proteins follow the surface adsorption mode while the hydrophobic proteins follow the insertion mode in the protein corona formation of Soluplus® nanomicelles.
An ethnoveterinary investigation into medicinal and aromatic plants used to treat livestock diseases by the local communities of the Rif, north of Morocco.
Submitted: 23 May 2022
Abstract: Show Abstract
Ethnopharmacological relevance: Phytotherapy has been playing a significant role in the livestock health care system for a long, especially in remote areas. This study aimed to document the therapeutic uses of plant species practised by the Rif's indigenous people to treat various veterinary health diseases.
Methods: Semi-structured questionnaires, field walks, and group discussions were conducted from June 2016 - to October 2019 to collect the data. Quantitative indices include Plant Part Value (PPV), Use value (UV), Fidelity Level (FL), Relative Popularity Level (RPL), Rank Order Priority (ROP), Jaccard Index (JI), and Informant Consensus Factor (ICF) were used for the data analysis.
Results: A total of 300 medicinal plants belonging to 205 genera and 67 families have been recorded with ethnoveterinary uses. Dominant families are Asteraceae (33 species), Lamiaceae (28 species), and Fabaceae (24 species). The reported illness was classified into 4 disease categories based on ICF values, and the highest number of plants was reported to treat internal parasites (ICF=0.967). Leaves were the most consistently used parts (PPV=48.4%). Aloysia citrodora Palau. (RPL=) had the highest RPL level (1.15).
Conclusions: It can be concluded that the local people of Rif hold rich ethnoveterinary knowledge to cure livestock diseases. Plant species with high FL, RPL, and UV values should be screened for comprehensive phytochemical and pharmacological studies to validate the ethnomedicinal knowledge.
Stochastic dynamics mass spectrometric 3D structural analysis of N-glycans of fetal bovine serum – an experimental and theoretical study
Submitted: 29 May 2022
Abstract: Show Abstract
The contribution addresses the problem of mass spectrometric (MS) 3D molecular and electronic structural analysis of mixtures of glycans of fetal bovine serum. The research task is unexpectedly difficult, due to random variation of non-template-driven glycosylation and fucosylation processes; a lack of regioselective derivatization, causing for mixtures of polydisperse glycans toward length and skeletal modifications; isomers of oligomers and polymers, including linear and branches molecular structures, respectively. That fact difficult significantly their structural analysis, mass spectromerically. Furthermore, MS phenomena of carbohydrates include reactions of intramolecular rearrangement and cylization, proton and charge transfer effects, noncovalent binded self-associates, alkali metal ion aducts, and multiply charged species under tandem MS/MS operation mode. Despite, the study presents a new line of plausible solution to the problem. It employs our innovative stochastic dynamic MS model formula D”SD = 2.6388.10-17.(<I2>–<I>2) capable of exactly quantifying fluctuations and temporal behaviour of measurable variable intensity (I) of analyte peaks. It has been shown, that it exactly and directly quantifies analyte concentration in solution and determines 3D molecular and electronic structures. The later task is less straightforward. It employs Arrhenius’s model equation within the framework of his transition state theory and the power capability of quantum chemical methods. The validity of the latter statements is examined, herein. The study, first, comes to grips MS collision-induced dissociation phenomena of mixtures of 2-aminobenzamide derivatized glycans. It utilizes ab initio and DFT static and molecular dynamics, molecular mechanics, and chemometrics, as well.
In vitro inhibitory effects on pancreatic lipase and α-glucosidase activity by extracts and fractions of Lavandula angustifolia L. from Southern Italy
Submitted: 27 Jun 2022
Abstract: Show Abstract
Lavandula angustifolia is one of the most popular medicinal plants, rich source of bioactive compounds. Most of the studies on lavender had focused on its essential oil and its use as a sleep aid, calmative, fragrant, insect repellant and flavoring agent. This work is aimed at investigating, for the first time, the potential role of L. angustifolia in the management of metabolic syndrome (MetS), one of the major and escalating public-health and clinical challenge worldwide. Herein, the aerial parts of L. angustifolia, collected in June 2021 in the “Parco Nazionale del Pollino”, Southern Italy, were subjected to extraction by maceration with ethanol. Then, the total extract was partitioned with solvents at different polarity such as n-hexane, dichloromethane and ethyl acetate. Extract and fractions were evaluated for their ability to inhibit alpha-glucosidase as well as lipase. The ethanol extract remarkably inhibited a-glucosidase and lipase (IC50 of 2.55 and 30.50 microg/ml, respectively) better than the positive control acarbose and orlistat (IC50 of 35.51 and 37.12 microg/ml, respectively). The most active fraction was dichloromethane with IC50 of 14.67 and 17.64 mg/ml, against alpha-glucosidase and lipase, respectively. Taking into account obtained results, L. angustifolia could be used for formulation of new products; however, further preclinical studies will be needed to confirm its in vivo efficacy, as well as to prove the safety of the tested extracts and fractions.
Prodrugs activated by vascular ectopeptidases: proof of concept
Submitted: 08 Sep 2022
Abstract: Show Abstract
Several vascular ectopeptidases reside in blood vessels and efficiently regulate peptide hormones. For instance, bradykinin (BK) is inactivated by angiotensin converting enzyme (ACE) or arginine-carboxypeptidases (Arg-CPs) and aminopeptidase N (APN) cleaves several substrates. Whether such peptidases may activate latent prodrugs of vasoactive agents has been tested. The contractility of the isolated human umbilical vein, radioligand binding assays, immunolocalization of peptidases, the internalization cycle of fluorescent receptors (microscopy), blood pressure measurements in anesthetized rats and specific inhibitors of peptidases have been exploited to show the feasibility of prodrug activation by vascular peptidases. L-Alanyl-histamine has virtually no affinity for the human histamine H1 receptor, but releases histamine and contracts the vein following cleavage by endogenous APN. Prolonged sequences of BK, such as BK-Arg, Arg0-BK-Arg-Arg and BK-His-Leu have little affinity for the BK B2 receptor but are contractile in the umbilical vein and hypotensive in anesthetized rats via their action on this receptor type following cleavage of the C-terminal extensions by Arg-CPs for the first two peptides, also by ACE for the last two. Vascular ectopeptidases were shown to activate latent agonists of the H1 and B2 receptors, a concept that could be extended to various classes of drugs for a local action on the vasculature.
By, , ,
By, , , , ,
By, , , , , , , , , , , , , , ,
By, , , , , , , ,
By, , , , , , ,
Welcome from the Chairs
Following the great success of the previous editions organized under the excellent chairmanship of Dr. Jean Jacques Vanden Eynde, we are pleased to cordially invite you to join us at 8th International Electronic Conference on Medicinal Chemistry, sponsored by the MDPI open access journal Pharmaceuticals. This platform seeks to provide a discussion forum for scientists from all over the world for recent developments and innovative ideas in Medicinal Chemistry. This will give students, researchers, and experts the opportunity to share their latest theories, results, models, and applications in this multidisciplinary area of knowledge. This is an entirely on-line conference that will be held during the month of November at https://ecmc2022.sciforum.net/. No registration fee is charged to participants, and there is the added advantage that there is no cost of flights, hotels, etc.
The conference will be organized around the aims and scope of the journal Pharmaceuticals, which include the following general topics:
Small molecules as drug candidates
Biomolecules, natural products, phages, and cells as therapeutic tools
Biological targets and biomarkers
Radiopharmaceutical sciences, radiochemistry, (hybrid) imaging, and nuclear medicine
Pharmacokinetics and pharmacodynamics
Pharmaceutical preparations and drug delivery
The format of the conference is as follows. Researchers are invited to provide a short abstract (250 words maximum without figures and without references) online at https://sciforum.net/user/submission from now until 21 September 2022 30 September 2022. Each participant can submit only one abstract as a presenting author and a maximum of three submissions per research group. All authors will be notified by 1 October 2022 with regard to the acceptance status of their abstract, at which point they will be asked to present their work (in English) in the form of a poster, a slideshow, or a video using the templates provided by the conference (see Instructions for Authors). All accepted submissions will be displayed online, open for discussion, comments, and questions, during the entire conference, at https://ecmc2022.sciforum.net/, on 1–30 November 2022.
All participants will be invited to submit a full paper describing their work. All submissions will be reviewed using the powerful text comparison tool iThenticate. This procedure aims to prevent scholarly and professional plagiarism. Submissions will then be peer-reviewed by conference committees based on originality/novelty, quality of presentation, scientific soundness, interest to the readers, overall merit and English level. Upon acceptance, submission will be published in a Special Issue “Selected Papers from the 8th International Electronic Conference on Medicinal Chemistry (ECMC2022)” covering the event in Pharmaceuticals (ISSN 1424-8247) sponsor of the conference . A 20% discount on the Article Processing Charge will be applied.
The most outstanding works, as selected by the scientific committee, will be rewarded with grants offered by the sponsoring journal Pharmaceuticals.
We look forward to engaging in exciting discussions and hearing new ideas and perspectives from experts in the field. All participants are welcome to join the online conference.
Dr. Alfredo Berzal-Herranz
Prof. Dr. Maria Emília Sousa
Call for Participations
The members of the Scientific Committee are pleased to announce this Call for Participation for the 8th International Electronic Conference on Medicinal Chemistry and to invite each researcher working in the exciting fields of medicinal chemistry and drug-related sciences to share their recent results with their colleagues all over the world.
The Conference will cover a wide range of aspects involved in drug discovery and development. A non-exhaustive list of topics that will be considered includes:
- Animal experimentation
- Assay development
- Chemical synthesis
- Clinical studies and side effects reports
- Combinatorial chemistry
- Drug delivery (including bioconjugates and prodrugs)
- High throughput screening
- Hit identification
- Imaging techniques
- In silico experiments
- In vitro and in vivo studies
- Lead optimization
- Pharmaceutical analysis
- Structure–activity relationships
Participation in the 8th International Electronic Conference on Medicinal Chemistry is absolutely free of charge for contributors and visitors. Researchers are invited to provide a short abstract (250 words maximum without figures and without references) online at https://www.sciforum.net/login from now until 21 September 2022 30 September 2022. Each participant can submit only one abstract as a presenting author and a maximum of three submissions per research group. Authors will be notified before 1 October with regard to the acceptance status of their abstract, at which point the author(s) will be asked to present their work (in English) in the form of a poster, a slideshow, or a video using the templates provided by the conference (see Instructions for Authors). All accepted submissions will be displayed online, at https://ecmc2022.sciforum.net/, on 1–30 November 2022.
Authors will be invited to publish their work as a review or a research article at a discounted price, in a Special Issue of the journal Pharmaceuticals.
The Scientific Committee looks forward to receiving contributions in response to this call and will be glad to provide any further information to interested parties. Questions may be addressed to the Pharmaceuticals editorial office at email@example.com.
We thank you in advance for your attendance to this conference and look forward to a stimulating exchange.
For information about the submission procedure and the preparation of a full presentation, please refer to the "Instructions for Authors".
Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), Spain
Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal
School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland
Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Portugal
Department of Environmental Biology, Sapienza University of Rome, Rome, Italy
Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Sweden
Helmholtz-Zentrum Dresden-Rossendorf (HZDR) e.V., Institute of Radiopharmaceutical Cancer Research, Germany
PharmaCampus Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Germany
Department of Pathology & Microbiology, University of Nebraska Medical Center, USA
Center of Health Sciences, Laboratory of Molecular Modeling and Computational Structural Biology, Federal University of Rio de Janeiro, Brazil
Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Finland
Department of Pharmacy, University of Chieti, Italy
Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, USDA‐ARS, 800 Buchanan St., Albany, CA 94710, USA
Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), PTS Granada, Av. Conocimiento, Granada, Spain
Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, Italy
Centro de Química Estrutural, Instituto Superior Técnico, Universidade Técnica de Lisboa, Portugal
Department of Biomolecular Sciences, University of Urbino Carlo Bo Piazza del Rinascimento, Italy
Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Turkiye
Institute for Biological System, Secondary office of Rome-Reaction Mechanisms, c/o Chemistry Dept Sapienza University of Rome, Italy
Center of Chemistry and Biochemistry, Faculdade de Ciências, Universidade de Lisboa, Portugal
Grupo de Pesquisas Químico-Farmacêuticas, GPQFfesp, Chemical and Pharmaceutical Sciences, Institute of Environmental, Federal University of São Paulo, Brazil
Department Oral Immunology and Infectious Diseases, School of Dentistry, University of Louisville, USA
Microbiology and Infectious Diseases, School of Systems Biology, George Mason University, USA
Theoretical Medicinal Chemistry, Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Germany
Group of Receptor Ligands for Molecular Imaging, European Institute for Molecular Imaging (EIMI), Muenster University, Germany
Group of Chemical biology of peptides and proteins, Department of Molecular Biology, Instituto de Parasitologia y Biomedicina "Lopez-Neyra" Spain
UCIBIO/REQUIMTE, Associate Laboratory i4HB - Institute for Health and Bioeconomy, MedTech-Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Portugal
IQ, Laboratório de Modelagem Molecular (LabMMol) - Sala 609, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, Cidade Universitária, Rio de Janeiro, Brazil
School of Pharmacy and School of Chemistry, University College Cork, Ireland
Docent in Structural Biology and Computational Biochemistry, Pharmaceutical Sciences Laboratory & Structural Bioinformatics Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Finland
School of Chemistry, Trinity College Dublin, Ireland
UCIBIO-REQUIMTE, Rede de Química e Tecnologia,Porto University, Portugal
Instructions for Authors
- Scholars interested in participating in the conference can submit their abstract (250 words maximum without figures and without references) online at this website until 21 September 2022 30 September 2022.
- Based on the submitted abstract, the conference committee will conduct a pre-evaluation of whether a contribution from the authors of the abstract will be welcome for 8th International Electronic Conference on Medicinal Chemistry. All authors will be notified by 1 October 2022 with regard to the acceptance status of their abstract.
- If the abstract is accepted for this conference, the author will be invited to prepare a full description of their work in the form of a poster, slideshow, or video at their best convenience, until the submission deadline of 12 October 2022.
- Posters must be uploaded as a PDF file using the Poster_template.pptx file available at the end of this section.
- Slideshows must be uploaded as a PDF file using the PPT_template.pptx file available at the end of this section.
- Flash communications (5 minutes) and communications (10-20 minutes) must be uploaded as an mp4/.webm/.ogg (max size: 250Mb) file (video) using the PPT_template.pptx file available at the end of this section.
- Tips for authors: if you would like to prepare a video based on your PowerPoint presentation, you may use the "record slide" function in PowerPoint.
This must be uploaded before 12 October 2022, for a final check and approval. Each work will be directed to the appropriate panel (posters, slideshows, flash communications, communications) by the Conference Office.
Contributions will be displayed on the website using Sciforum.net’s proprietary slides viewer and will be accessible at https://ecmc2022.sciforum.net/ at the time of the conference. They can be prepared in exactly the same way as for any traditional conference where research results can be presented. Contributions must be converted to PDF format before submission, so that they can be easily and automatically converted to be displayed online.
The organization of posters is left completely up to the authors, provided that they use the conference’s template.
The accepted contributions will probably be published as one dedicated volume in the MDPI Medical Sciences Forum journal. Publication of proceedings paper is free of charge.
Note: Before publication, Medical Sciences Forum journal will review accepted papers using the powerful text comparison tool: iThenticate. This procedure aims to prevent scholarly and professional plagiarism.
Submissions with a high repetition rate and lack of novelty will not be published in the conference proceedings.
Certificate of Attendance : After the event, the participants of ECMC 2022 will be able to download an electronic Certificate of Attendance by logging in to your Sciforum personal account. Once you are logged-in, go to your profile and click on 'My certificates'. A list of all Sciforum events you have attended is available and you simply have to click on "Download" next to the correct event.
We recommend the following organization for your slideshow, poster or video, using the Conference’s template:Slides
- Length of the presentation: no more than 30 slides
- Slides can be prepared the same way as for any traditional conference. They should be converted into a PDF format before submission.
- Slide 1 (strictly one slide): Title, authors’ names, affiliation(s), email address of corresponding author, logos of the laboratory and/or institution (not mandatory).
- Slide 2 (strictly one slide): Graphical abstract; repeat the title of the presentation but avoid other text as far as possible.
- Slide 3 (strictly one slide): Abstract (max. 250 words) and 3–5 keywords, separated by semicolons.
- Slide 4 and following slides: These should contain (in the given sequence) Introduction, Results and Discussion, Conclusions.
- Last slide: Acknowledgments, and logos of sponsors (not mandatory).
Posters will be available on this conference website during and after the event. Like papers presented on the conference, participants will be able to ask questions and make comments about the posters. Posters can be presented without an accompanying proceedings paper.
The poster should be in PDF format
- The minimum size for images is 148 mm × 210 mm (horizontal × vertical) at 300 dpi.
- The content of the poster should be a comprehensive presentation of your accepted submission.
- No copyright issues with any elements in the poster.
The following awards will be offered by our organizers.
Number of Awards Available: 5The open access peer-reviewed Journal Pharmaceuticals will offer each one award (400 CHF) to reward the best poster, the best slideshow, the best flash communication and the best communication, and 500 CHF to reward the best invited lecture. All submissions will be considered, independently of the session (general and round table). The best works will be selected by the members of the Scientific Committee.
Number of Awards Available: 1One free 1-day hands on/testing using microwaves offered by Microwave Technologies Consulting. Selection will be made by the Company following strict scientific criteria.
Ms. Amber Zhao
Ms. Jennifer Wang
S1. Opening session
Prof. Dr. Maria Emília Sousa
Dr. Alfredo Berzal-Herranz
S2. Invited lectures
Prof. Dr. Maria Emília Sousa
Dr. Alfredo Berzal-Herranz
Dr. Jong Heon Kim
S4. Small molecules as drug candidates
Prof. Dr. Mary J. Meegan
Dr. Daniela De Vita
S5. Biomolecules as therapeutics
Prof. Dr. Amélia Pilar Rauter
Dr. Cristina Romero-López
S6. Emerging technologies in drug discovery
Prof. Dr. Joachim Jose
Prof. Dr. Osvaldo Andrade Santos-Filho
Dr. Klaus Kopka
S8. Pharmaceutical development
Prof. Dr. Jessica Rosenholm
On behalf of the chairs of the 8th International Electronic Conference on Medicinal Chemistry (ECMC-8), we are pleased to announce the winners of the Conference Award:
Best Poster Award
- Marie Hanot et al., "Development of New Anti-virulence Agents to Tackle Multi-resistant Pseudomonas Aeruginosa".
Marie Hanot is a second-year Ph.D. student in Medicinal Chemistry, in the team of Pr. Pascal Sonnet (AGIR, UR4294) at the Faculty of Pharmacy of the University of Picardie Jules Verne (France). Marie’s research focuses on the development of anti-virulence agents to combat pseudomonal multi-drug resistance. Marie holds a B.Sc. degree in chemistry from the same institution as well as a M.Sc. degree in Chemistry, Biology and Drugs from the University of Strasbourg (France).
Best Slideshow Award
- Maddalena Paolillo et al., "Binding to Proteins of the Pharmacologically Active Bis(Maltolato) Oxidovanadium(IV)".
The presenting author, Maddalena Paolillo, is a first-year Ph.D. student in Chemical Sciences from Department of Chemical Sciences of University of Naples Federico II (Italy). She is working under the supervision of Prof. Antonello Merlino and Prof. Filomena Sica.
She holds a master’s degree in chemical sciences (2022), with a thesis on the refinement of crystal structures of adducts formed upon reaction of model proteins with a vanadium compound of medical interest. The topic of her Ph.D. is focused on the study of the mechanism of action of different V-based drugs by analyzing, both in solution and at solid state, their interaction with biological macromolecules.
Best Flash Communication Award
- Fabian Krutzek et al., "Small Molecule Radiotracers for PET Imaging of PD-L1 with Copper-64”.
Fabian Krutzek studied Chemistry at the University of Heidelberg and obtained 2019 his Master degree in organic chemistry. Currently he is a fourth-year PhD student at the Helmholtz Center Dresden-Rossendorf under supervision of Prof. Dr. Klaus Kopka. His research project focuses on design, synthesis, and evaluation of small molecule-based radiotracers for imaging PD-L1 in cancer patients. This project requires a high level of synthetic organic chemistry, with up to 25 synthetic steps per molecule. In the interdisciplinary field of medicinal radiochemistry, he developed skills in radiochemical labeling and obtained basic knowledge in computational methods as well as cell-based assays. Through collaboration with biologists, he gained theoretical knowledge on the conduction and analysis of data from animal studies. Currently in the final months of his Ph.D. studies, he plans to pursue post-doctoral studies abroad in a related field of organic chemistry.
Best Communication Award
-Ana Marta de Matos et al., "C-Glucosyl Flavone Derivatives as Non-PAIN Therapeutic Leads for Alzheimer’s Disease".
Ana Marta de Matos graduated in Biochemistry in 2011 at FCUL and completed her M.Sc. degree in Medicinal Chemistry at FFUL in 2013. She then returned to FCUL where she pursued her Ph.D. in Organic Chemistry with a focus on the synthesis and biological evaluation of new sugar-based polyphenols with bioactivity against type 2 diabetes and Alzheimer’s disease. During her path as a Ph.D. student, she spent nine months at Eli Lilly’s Neuroscience Research Centre in Windlesham, UK, where she worked closely with some of the best Medicinal Chemists in the World. She completed her Ph.D. in 2019, published her results in high-quality peer-reviewed scientific journals in the field, and won the FCiências.ID award for Best Ph.D. Thesis in Chemistry in 2019. In July 2021, Ana received a research contract to initiate her career as an independent researcher at Centro de Química Estrutural (CQE), from the Institute of Molecular Sciences (IMS), FCUL. One year later, she was awarded a contract in the highly competitive FCT call 'Scientific Employment Stimulus 2022’, having also been nominated as shadow coordinator of the Carbohydrate Chemistry Group of CQE, FCUL. Ana Marta is currently interested in developing new carbohydrate-based compounds against infections caused by multidrug-resistant Gram-negative bacteria.
Best Invited Lecture Award
Dr Tim O’Sullivan received his BSc Degree in Industrial Chemistry from the University of Limerick in 1997. He then went on to do a PhD in natural products synthesis under the supervision of Prof. Lew Mander at the Research School of Chemistry of the Australian National University from 1998 to 2001. He worked as a postdoctoral researcher on the synthesis of Tamoxifen analogues with Prof. Mary Meegan in Trinity College Dublin from 2001 before taking up another postdoctoral fellowship with Prof. Pat Guiry in University College Dublin on the synthesis of novel Lipoxin analogues in 2003 . Following a period as research manager in UCD, he was appointed as Lecturer in Pharmaceutical Chemistry in the School of Pharmacy/Department of Chemistry/ABCRF in UCC in 2006. He is a member of the Royal Society of Chemistry, the Marie Curie Alumni Association and COST Action 'CA21145 European Network for diagnosis and treatment of antibiotic-resistant bacterial infections (EURESTOP)'. His research is focussed on developing new methods and strategies for the synthesis of bioactive, natural products. The underlying goal in this work is to improve upon existing techniques and to discover novel methods for assembling complex molecular targets. The ultimate aim is to apply this knowledge to the development of more potent analogues of existing compounds, with a view to producing pharmaceutically relevant therapeutic agents.
One free 1-day hands on/testing using microwaves offered by Microwave Technologies Consulting
-Rosa Tundis et al., "In vitro inhibitory effects on pancreatic lipase and α-glucosidase activity by extracts and fractions of Lavandula angustifolia L. from Southern Italy ".
-Maria Mernea et al., "A molecular docking study on natural compounds as anxiolytics and antidepressants ".